Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M705Revenue $M2.6Net Margin (%)0Z-Score39.3
Enterprise Value $M564EPS $-0.6Operating Margin %0F-Score4
P/E(ttm))0Cash Flow Per Share $-0.6Pre-tax Margin (%)0Higher ROA y-yY
Price/Book5.110-y EBITDA Growth Rate %-37.3Quick Ratio15.0Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %-6.5Current Ratio15.0Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-36.3Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-38.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M96.8ROI % (ttm)-50.2Gross Margin Increase y-yN

Gurus Latest Trades with ACHN

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ACHNJean-Marie Eveillard 2014-03-31 Sold Out -0.01%$3.08 - $4.2
($3.5)
$ 7.28108%Sold Out0
ACHNJean-Marie Eveillard 2013-12-31 Buy 0.01%$2.43 - $3.46
($2.9)
$ 7.28151%New holding, 600000 sh.600,000
ACHNJohn Burbank 2012-12-31 Sold Out -0.24%$7.2 - $11.1
($8.86)
$ 7.28-18%Sold Out0
ACHNJohn Burbank 2012-09-30 Buy 0.24%$5.61 - $10.41
($7.06)
$ 7.283%New holding, 500000 sh.500,000
ACHNGeorge Soros 2012-06-30 Sold Out -0.04%$5.94 - $10.95
($7.34)
$ 7.28-1%Sold Out0
ACHNGeorge Soros 2012-03-31 Reduce-0.09%$7.71 - $12.375
($9.57)
$ 7.28-24%Reduce -50%250,000
ACHNGeorge Soros 2011-12-31 Add0.16%$4.01 - $8
($6.15)
$ 7.2818%Add 2132.14%500,000
ACHNGeorge Soros 2011-09-30 Buy $4.63 - $8.31
($6.37)
$ 7.2814%New holding, 22400 sh.22,400
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ACHN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ACHN Jean-Marie Eveillard 2014-03-31000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


ACHN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
RA CAPITAL MANAGEMENT, LLCSee Footnotes (1)(5) 2014-06-20Sell880,000$8.4-13.33view
QVT Associates GP LLC10% Owner 2014-06-16Sell1,819,551$7.7-5.45view
Truitt JosephEVP, Chief Commercial Officer 2014-06-16Sell25,000$7.82-6.91view
FRASHIER GARY EDirector 2014-06-16Sell55,000$8-9view
QVT Associates GP LLC10% Owner 2014-06-11Sell128,649$7.66-4.96view
KISHBAUCH MICHAEL DDirector 2014-06-10Sell371,937$7.75-6.06view
Truitt JosephEVP, Chief Commercial Officer 2014-06-10Sell50,000$6.0220.93view
QVT Associates GP LLC10% Owner 2013-12-30Sell170,239$3.34117.96view
QVT Associates GP LLC10% Owner 2013-12-26Sell121,205$3.44111.63view
QVT Associates GP LLC10% Owner 2013-12-23Sell289,141$3.24124.69view

Press Releases about ACHN :

    Quarterly/Annual Reports about ACHN:

    News about ACHN:

    Articles On GuruFocus.com
    Top 4 Insider Buys of Last Week Jun 10 2013 
    comment on ACHN Mar 15 2013 
    comment on ACHN Mar 09 2013 
    Achillion Will Surge If New Drug Is Successful Apr 21 2012 
    Weekly CEO Sells Highlight: Achillion Pharmaceuticals Inc, Monster Beverage Corp, CarMax Inc, and Im Jan 23 2012 
    Weekly CEO Sells Highlight: UNH, LRY, ACHN, RPM Jan 16 2012 
    Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Oct 27 2010 
    Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 13 2010 
    Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 03 2009 
    Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) May 15 2009 

    More From Other Websites
    Nasdaq stocks posting largest percentage increases Jul 30 2014
    The Federal Reserve Playing Analyst Damaging to Biotechnology Companies Jul 30 2014
    Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline Jul 03 2014
    Achillion Pharmaceuticals Added to the Russell 2000 and Russell Microcap Indexes Jul 01 2014
    Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly Jun 27 2014
    [video] 3 Reasons for Russell 2000 surge Jun 20 2014
    Achillion Could Win Idenix's Mystery Suitor: Analyst Jun 20 2014
    Speculators On The Next HCV Acquisition Should Not Overlook Technological Platforms Jun 20 2014
    Idenix received bid above $18.00 per share prior to deal with Merck Jun 20 2014
    Maxim's $22 Price Target On Achillion Is Far From Realistic Jun 17 2014
    Achillion Gets Massive Price Target Hike On HCV Drugs Jun 16 2014
    Achillion gets price target hike Jun 16 2014
    If Achillion Was Going To Be Taken Out At A Big Premium, Baupost Would Probably Own It Jun 16 2014
    [$$] Achillion Set to See Shares Soar Jun 16 2014
    Why Achillion Pharmaceuticals (ACHN) Is Spiking Today Jun 16 2014
    Achillion price target raised to $22 from $6 at Maxim Jun 16 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide